Skip to main content
SpringerLink
Log in

CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers

  • Protocol
  • First Online:
Book cover Chimeric Antigen Receptor T Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2086))

Abstract

Immunotherapy has been growing in the past decade as a therapeutic alternative for cancer treatment. In this chapter, we deal with CAR-T cells, genetically engineered autologous T cells to express a chimeric receptor specific for an antigen expressed on tumor cell surface. While this type of personalized therapy is revolutionizing cancer treatment, especially B cell malignancies, it has some challenging limitations. Here, we discuss the basic immunological and technological aspects of CAR-T cell therapy, the limitations that have compromised its efficacy and safety, and the current proposed strategies to overcome these limitations, thereby allowing for greater therapeutic application of CAR-T cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mathis S, Vallat JM, Magy L (2016) Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy. Immunotherapy 8:165–178

    Article  CAS  PubMed  Google Scholar 

  3. Kershaw MH, Westwood JA, Slaney CY et al (2014) Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 3:e16

    Article  PubMed  PubMed Central  Google Scholar 

  4. Batlevi CL, Matsuki E, Brentjens RJ et al (2015) Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13:1–17

    Google Scholar 

  5. Maus MV, Grupp SA, Porter DL et al (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123:2625–2635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453–1464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Long AH, Haso WM, Shern JF et al (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fesnak A, Lin CY, Siegel DL et al (2016) CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev 30(3):139–145

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bryn T, Yaqub S, Mahic M et al (2008) LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol 20(2):235–245

    Article  CAS  PubMed  Google Scholar 

  11. Dehghani M, Sharifpour S, Amirghofran Z et al (2012) Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin’s lymphoma patients. Med Oncol 29:2364–2371

    Article  PubMed  Google Scholar 

  12. Golubovskaya V, Wu L (2016) Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancer 8(3):E36

    Article  Google Scholar 

  13. Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: Building the ultimate antitumour T cell. Nat Rev Cancer 12(10):671–684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Xu Y, Zhang M, Ramos CA (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR CD19-T cells and are preserved by IL-7 and IL-15. Blood 123(24):3750–3759

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Turtle CJ, Hanafi LA, Berger C (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123–2138

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sommermeyer D, Hudecek M, Kosasih PL et al (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2):492–500

    Article  CAS  PubMed  Google Scholar 

  17. Grupp SA, Kalos M, Barret D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sun Z, Wang S, Zhao RC (2014) The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol 7:14

    Article  PubMed  PubMed Central  Google Scholar 

  19. Morgan RA, Yang JC, KItano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Maude SL, Barrett D, Teachey DT et al (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20:119–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. U.S. Food & Drug Administration (2017) Kymriah (tisagenlecleucel). https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm573706.htm

  22. Nassereddine S, Rafei H, Elbahesh E et al (2017) Acute graft versus host disease: a comprehensive review. Anticancer Res 37(4):1547–1555

    Article  CAS  PubMed  Google Scholar 

  23. Poirot L, Philip B, Schiffer-Mannioui C et al (2015) Multiplex genome-edited T-cell manufacturing platform for ‘off-the-shelf’ adoptive T-cell immunotherapies. Cancer Res 75(18):3853–3864

    Article  CAS  PubMed  Google Scholar 

  24. Graham C, Yallop D, Jozwik A (2017) Preliminary results of UCART19, an allogeneic Anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia. Blood 130:887

    Google Scholar 

  25. Davila ML, Riviere I, Wang X (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lee DW, Kochenderfer JN, Stetler-Stevenson M (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528

    Article  CAS  PubMed  Google Scholar 

  27. Barlow B, Barlow A, Freyer C (2018) CAR-T cells: driving a new era of oncology immunotherapy. US Pharm 43(11):15–22

    Google Scholar 

  28. Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321–3330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Neelapu SS, Tummala S, Kebriaei P (2018) Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47–62

    Article  CAS  PubMed  Google Scholar 

  30. Viaud S, Ma JSY, Hardy IR (2018) Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc Natl Acad Sci 115(46):E10898–E10906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee YG, Marks I, Srinivasarao M et al (2019) Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res 79(2):387–396

    Article  CAS  PubMed  Google Scholar 

  32. Zhang E, Xu H (2017) A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol 10(1):1

    Article  PubMed  PubMed Central  Google Scholar 

  33. Yeku OO, Purdon T, Spriggs DR et al (2018) Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer. J Clin Oncol 36(5):12

    Article  Google Scholar 

  34. Hegde M, Mukherjee M, Grada Z (2016) Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest 126(8):3036–3052

    Article  PubMed  PubMed Central  Google Scholar 

  35. Cho JH, Collins JJ, Wong WW (2018) Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173(6):1426–1438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Moon EK, Carpenito C, Sun J et al (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719–4730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Caruana I, Savoldo B, Hoyo V et al (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5):524–529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was financially supported by FAPESP (2012/23228-4, 2016/08374- 5, 2017/09491-8), CTC Center for Cell-based Therapies (FAPESP 2013/08135-2) and National Institute of Science and Technology in Stem Cell and Cell Therapy (CNPq 573754-2008-0 and FAPESP 2008/578773). The authors also acknowledge financial support from Secretaria Executiva do Ministério da Saúde (SE/MS), Departamento de Economia da Saúde, Investimentos e Desenvolvimento (DESID/SE), Programa Nacional de Apoio à Atenção Oncológica (PRONON) Process 25000.189625/2016-16.

Author information

Authors and Affiliations

  1. Center for Cell-Based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

    Virgínia Picanço-Castro & Dimas Tadeu Covas

  2. School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

    Kamilla Swiech & Kelen Cristina Ribeiro Malmegrim

  3. Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

    Dimas Tadeu Covas

Authors
  1. Virgínia Picanço-Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamilla Swiech
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelen Cristina Ribeiro Malmegrim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimas Tadeu Covas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virgínia Picanço-Castro .

Editor information

Editors and Affiliations

  1. School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

    Kamilla Swiech

  2. School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

    Kelen Cristina Ribeiro Malmegrim

  3. Center for Cell-Based Therapy CTC Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

    Virgínia Picanço-Castro

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Picanço-Castro, V., Swiech, K., Malmegrim, K.C.R., Covas, D.T. (2020). CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers. In: Swiech, K., Malmegrim, K., Picanço-Castro, V. (eds) Chimeric Antigen Receptor T Cells. Methods in Molecular Biology, vol 2086. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0146-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0146-4_1

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0145-7

  • Online ISBN: 978-1-0716-0146-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation